期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

治疗肾细胞癌新药:血管内皮生长因子受体抑制剂tivozanib 被引量：1

A new drug in treatment of renal cell carcinoma: vascular endothelial growth factor receptor inhibitor tivozanib
原文传递
导出
摘要 tivozanib为选择性血管内皮生长因子受体(VEGFR)抑制剂,由AVEO制药公司生产,于2017年8月28日获欧盟、冰岛及挪威药品管理局批准用于治疗成人晚期肾细胞癌。本文从药效学、药动学、临床疗效及安全性等方面对tivozanib进行介绍。 Tivozanib is a selective vascular endothelial growth factor receptor（VEGFR） inhibitor.It was developed by AVEO Pharmaceuticals.Tivozanib was approvaled by the EU,Iceland and Norway medicines agency for the treatment of adult patients with advanced renal cell carcinoma on August 28,2017.This article summarized the pharmacodynamics,pharmacokinetics,clinical efficacy and safety of tivozanib.
作者 杨君义 YANG Jun-yi(Department of Pharmacy,Central Hospital of Linyi City,Y ishui SHA NDONG 276400,China)
机构地区 临沂市中心医院药学部
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2018年第10期541-543,共3页 Chinese Journal of New Drugs and Clinical Remedies
关键词 tivozanib 癌 肾细胞 受体 血管内皮生长因子 tivozanib carcinoma renal cell receptors vascular endothelial growth factor
分类号 R737.11 [医药卫生—肿瘤]
  • 相关文献

参考文献3

二级参考文献39

  • 1李恩孝,施璠,吴胤瑛.靶向抗VEGFR治疗恶性肿瘤的研究进展[J].现代肿瘤医学,2006,14(2):234-236. 被引量：6
  • 2Campas C,Bolos J,Castaner R,et al.Tivozanib[J].Drugs Fut,2009,34(10):793-796.
  • 3Matsunags N.N-[(6,7)-dimethoxy-4-quinolyl]phenyl]-N-(5-methyl-3-isoxazolyl)urea salt in crystalline form[P].US:2006052415,2006-03-09.
  • 4Suzuki R.Structure-activity relationship and antitumoractivities of azolyl quinoline-urea derivatives as novelorally active selective VEGF receptor tyrosine kinaseinhibitors[R].Tsukuba:23rd Med Chem Symp,2004.
  • 5Kubo K,Sakai T,Hasegawa K,et al.Quinoline derivativehaving azolyl group and quinazoline derivative[P].WO:2002088110,2002-11-07.
  • 6Kazuhide N,Eri T,Toru M,et al.KRN951,a highlypotent Inhibitor of vascular endothelial growth factorreceptor tyrosine kinases,has antitumor activities andaffects functional vascular properties[J].Cancer Res,2006,66(18):9134-9142.
  • 7Eri T,Kazuhide N,Kazumi T,et al.A novel orally activeinhibitor of VEGF receptor tyrosine kinases KRN951:Anti-angiogenic and anti-tumor activity against human solidtumors[J].Proc Amer Assoc Cancer Res,2004,45:2575.
  • 8Kazuhide N,Eri T,Kazumi T,et al.In vitro selectivityand potency of KRN951,a novel inhibitor of VEGFreceptor tyrosine kinases[J].Proc Amer Assoc CancerRes,2004,45:2571.
  • 9Eri T,Kazuhide N,Toru M,et al.Anti-tumor activity andtumor vessel normalization by the vascular endothelialgrowth factor receptor tyrosine kinase inhibitor KRN951in a rat peritoneal disseminated tumor model[J].CancerSci,2008,99(3):623-630.
  • 10Robinson M,Lin J,Yang H,et al.Combination treatmentof VEGFR inhibitor AV-951 and rapamycin revealsdistinct mechanisms of each agent’s anti-tumor activity[J].Eur J Cancer Suppl,2008,6(12):53.

共引文献14

同被引文献5

引证文献1

二级引证文献1

中国新药与临床杂志
2018年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部